Filing Flows › Companies › Royalty Pharma › Analysis traps
Royalty Pharma (RPRX): analysis traps
Where its figures could mislead a reader, and what to check before taking them at face value · Data: Q3 2026, to Sep 30, 2026, filed Nov 4, 2026; rules v1.1
Royalty Pharma (RPRX): 0 rules of 10 triggered on the filings to Sep 30, 2026. 1 to review; 3 with insufficient data; 2 not applicable. Each is a question to verify, with the normal explanation that would produce the same figures.
Check these first
A precise DCF value = the true value To review · confidence high
The DCF's point value is 42.81 a share (price 67.30); 77% of it is the terminal value, a number about years no one has seen. Moving wacc by ±1 pt alone takes it from 31.70 to 60.37; across every method the research ran the range is -9 to 94. The value is a range; the decimals are not information.
Innocent reading: A stable, mature business with a narrow range of outcomes, where the point value is a fair summary.
Every rule
A01 FCF growth = the business improved Insufficient data
fewer than two fiscal years with operating cash flow and capital expenditure on file
A07 Stock compensation added back = no economic cost Not triggered confidence high
Stock compensation is 12.2% of revenue, but buybacks of $1.2B covered it (4.2×) and the diluted share count fell 5.0%: the dilution has been paid for in cash.
The figures and how they are read
| Fiscal year | FY2025 |
| Stock compensation | $290M |
| Revenue | $2.4B |
| SBC / revenue | +12.2% |
| Buybacks | $1.2B |
| Buybacks / SBC | 4.2 |
| Diluted shares, year before | 594.1M shares |
| Diluted shares | 564.5M shares |
| Diluted shares: change | -5.0% |
SBC / revenue from the cash flow statement's add-back; the diluted weighted share count year over year; buybacks from the financing section
Source: FY2025 (stock compensation, buybacks and the diluted share count, fiscal year)
B02 Receivables growing = future cash is certain Insufficient data
fewer than five quarters with receivables and revenue on file (a year-over-year comparison needs five)
B08 Adjusted profit = economic profit Insufficient data
no reconciliation table read from the releases yet and fewer than three quarters with both an adjusted and a GAAP EPS
C02 Low net debt = no refinancing risk Not triggered confidence medium
$997M comes due within a year, 3.5× covered by cash and investments of $545M plus $3.0B of free cash flow.
The figures and how they are read
| Cash and investments | $545M |
| Debt | $8.6B |
| Net debt | $8.0B |
| Due within a year | $997M |
| Read from | the current portion of debt on the balance sheet |
| Free cash flow, twelve months | $3.0B |
| Cash plus free cash flow | $3.5B |
| Coverage of what is due | 3.5 |
| Due in the second year | — |
| Balance sheet date | 2026-09-30 |
due within a year from the maturity table (else the current portion of debt), against cash and investments plus free cash flow over the last twelve months (zero if negative); no credit lines assumed
Source: 2026-09-30 (debt maturities, cash and investments)
D03 EPS growth = profit growth Not triggered confidence high
EPS fell 49% and net income fell 49% in Q3 2026; the share count fell 0.5%: EPS growth follows profit growth.
The figures and how they are read
| Quarter | Q3 2026 |
| Quarter before | Q3 2025 |
| EPS, year before | $0.51 |
| EPS | $0.26 |
| Net income, year before | $284M |
| Net income | $145M |
| Diluted shares, year before | 559.6M shares |
| Diluted shares | 557.0M shares |
| EPS growth | -48.8% |
| Net income growth | -49.1% |
| Diluted shares: change | -0.5% |
| eps from profit | -$0.25 |
| eps from share count | $0.00 |
EPS and net income against the same quarter a year earlier; the EPS bridge attributes the change to profit first, then to the share count (the order is fixed and disclosed)
Source: Q3 2026 (net income, diluted shares, EPS) · Q3 2025 (the same quarter a year earlier)
E02 Low P/E at a cyclical peak = undervalued Not triggered confidence medium
Net income of $668M is not at a cyclical high against the last eight years (median $975M, best $2.3B): the P/E of 56.1× is on a normal year.
The figures and how they are read
| market value | $37.5B |
| net income ttm | $668M |
| pe ttm | 56.10 |
| net income median fy | $975M |
| pe mid cycle | 38.40 |
| net income peak fy | $2.3B |
| years | FY2018 / 1378.0; FY2019 / 2349.0; FY2020 / 975.0; FY2021 / 620.0; FY2022 / 43.0; FY2023 / 1135.0; FY2024 / 859.0; FY2025 / 771.0 |
| down years in window | 5 |
P/E on the trailing twelve months' net income against the P/E on the median net income of the last eight fiscal years (a mid-cycle stand-in); 'at a peak' = this year's profit at or above 90% of the best year and at least 1.3× the median
Source: Q3 2026 (net income, trailing twelve months)
E07 A precise DCF value = the true value To review confidence high
The DCF's point value is 42.81 a share (price 67.30); 77% of it is the terminal value, a number about years no one has seen. Moving wacc by ±1 pt alone takes it from 31.70 to 60.37; across every method the research ran the range is -9 to 94. The value is a range; the decimals are not information.
The figures and how they are read
| dcf value | 42.81 |
| price | 67.30 |
| terminal value share | +77.5% |
| swing by input | WACC / ±1 pt / 31.7 / 60.37; Revenue growth (each year) / ±5 pts / 30.83 / 57.1; Operating margin / ±3 pts / 39.52 / 46.11; Terminal growth / ±0.5 pt / 40.57 / 45.59 |
| range all methods | -9.03; 93.54 |
the DCF's point value against the share of it that is the terminal value and the value at each input moved by one step (growth ±5 pts, WACC ±1 pt, margin ±3 pts …); the range across every method the research ran
Source: 2026-11-08 (valuation research)
What would explain it innocently
- A stable, mature business with a narrow range of outcomes, where the point value is a fair summary
- The inputs that matter most are themselves well known (a regulated return, a long contract)
What to look for in the filing
- Which input you believe differs from the research's and why
- What the price implies for growth (the reverse DCF on the fair-value page)
What would show the trap does not apply
- The DCF's value is robust to the terminal growth and discount rate (the range's low end is still above the price)
- The company's cash flows over the next three years track the DCF's early years
Look again: next filing.
J06 A bank's low P/E and high profit = safe Not applicable
not a bank
J08 A REIT's low net income = the dividend is unsafe Not applicable
not a REIT
What the statuses mean
Triggered: the filings show the pattern; read the normal explanations and the missing evidence before concluding anything. To review: one quarter or a weak signal; a reader's judgement, not a pattern. Not triggered: the pattern is absent on these figures. Insufficient data: the filings read so far do not hold what the rule needs; this is not a clean bill. Not applicable: the rule is not meant for this kind of company (a bank's working capital, a loss-making quarter's EPS growth). Out of date: the latest filing is more than fifteen months old.
Severity is what the pattern could mean for cash, value or solvency; confidence is how reliable the inputs and the reading are. The two are kept apart.
Record a view
A reader's judgement, grounds, what would change it and the next review; kept in the browser (needs JavaScript).
Every rule and the companies it triggers on → Royalty Pharma: cash flow →
Each rule reads the company's own filings by a fixed formula and says what would explain the same figures innocently. A triggered rule is a question to verify, not a finding of manipulation, and not a view on the stock. Missing data is shown as missing, never as clear. Not investment advice.